Quanterix
Generated by Meeveem AI
"Advancing precision biomarker detection from research to diagnostics with unmatched sensitivity"
About Quanterix
Quanterix develops sensitive biomarker detection technology for disease research, diagnostics and drug development. Its Simoa platforms measure proteins in blood and cerebrospinal fluid, while spatial biology systems analyse tissue. These complementary technologies support work in neurology, oncology and immunology, including clinical trials and diagnostic development.
Established in 2007 and headquartered in Billerica, MA, Quanterix serves pharmaceutical companies, research organisations and diagnostic laboratories worldwide. Its 2025 acquisition of Akoya Biosciences added multiplexed tissue imaging with single-cell resolution. The combined portfolio connects liquid and spatial analysis, alongside laboratory services and Lucent Diagnostics’ Alzheimer’s blood testing. Quanterix reports more than 2,300 instruments deployed globally.
From laboratory to customer
Quanterix recruits across assay development, diagnostics, engineering, manufacturing, laboratory services and quality, alongside commercial and support functions. Its work connects instrument and assay development with the teams that manufacture, distribute and support those products.
Learning across the business
The company describes career growth and learning on the job as part of its approach to talent development. Its careers page also lists tuition reimbursement to support continuing study, alongside mental health resources including coaching and therapy sessions.
450
Team Members
2007
Founded
Diagnostics
Sector
Hybrid
Work Environment